ES2556770T3 - Expresión híbrida y en tándem de proteínas procedentes de Neisseria - Google Patents
Expresión híbrida y en tándem de proteínas procedentes de Neisseria Download PDFInfo
- Publication number
- ES2556770T3 ES2556770T3 ES10179788.4T ES10179788T ES2556770T3 ES 2556770 T3 ES2556770 T3 ES 2556770T3 ES 10179788 T ES10179788 T ES 10179788T ES 2556770 T3 ES2556770 T3 ES 2556770T3
- Authority
- ES
- Spain
- Prior art keywords
- patent application
- international patent
- protein
- seq
- proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract description 14
- 102000004169 proteins and genes Human genes 0.000 title abstract description 12
- 241000588653 Neisseria Species 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 description 10
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000001322 periplasm Anatomy 0.000 description 2
- 101100039010 Caenorhabditis elegans dis-3 gene Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WPNJAUFVNXKLIM-UHFFFAOYSA-N Moxonidine Chemical compound COC1=NC(C)=NC(Cl)=C1NC1=NCCN1 WPNJAUFVNXKLIM-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000588654 Neisseria cinerea Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000588649 Neisseria lactamica Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229940031670 conjugate vaccine Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000001459 mortal effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004781 supercooling Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Una composición que comprende las siguientes proteínas: (1) NH2-A-[X-L-]n-B-COOH, en la que n>= 2, X1>= 287, X2>= 953 (2) 961 (3) NH2-A-[X-L-]n-B-COOH, en la que n>= 2, X1>= 936, X2>= 741, en la que 287 es la SEC ID Nº: 3104 del documento WO99/57280 o una proteína que tiene una identidad de secuencia de un 80 % o más con ella, 953 es la SEC ID Nº: 2918 del documento WO99/57280 o una proteína que tiene una identidad de secuencia de un 80 % o más con ella, 961 es la SEC ID Nº: 940 del documento WO99/57280 o una proteína que tiene una identidad de secuencia de un 80 % o más con ella, 936 es la SEC ID Nº: 2884 del documento WO99/57280 o una proteína que tiene una identidad de secuencia de un 80 % o más con ella, 741 es la SEC ID Nº: 2536 del documento WO99/57280 o una proteína que tiene una identidad de secuencia de un 80 % o más con ella, y en la que cada L es una secuencia de aminoácidos engarzadora opcional, A es una secuencia de aminoácidos N-terminal opcional y B es una secuencia de aminoácidos Cterminal opcional.
Description
5
10
15
20
25
30
35
contra diversas cepas:
- 2996(B)
- MC58(B) NGH38 394/98(B) H44/76(B) F6124(A) BZ133(C) C11(C)
- (1)
- 32000 16000 130000 16000 32000 8000 16000 8000
- (2)
- 256 131000 128 16000 32000 8000 16000 <4
- (3)
- 32000 8000 - - - 8000 - 32000
- mezcla
- 32000 32000 65000 16000 260000 65000 >65000 8000
- (X)
- 4000 4000 1000 1000 >4000 1000 4000 n.d.
- ’-’ indica que esta cepa no contiene el gen NadA (X) era una combinación de la proteína 287 con vesículas de membrana externa, para comparar
Considerando los ratones individualmente, la mezcla indujo títulos bactericidas elevados y uniformes:
- Nº
- 1 2 3 4 5 6 7 8 9 10
- 2996
- 32768 16384 65536 32768 32768 65536 65536 32768 65536 8192
- MC58
- 65536 32768 65536 65536 65536 18192 65536 32768 132768 65536
- 394/98
- 65536 4096 16384 4096 8192 4096 32768 16384 8192 16384
961 no está presente en la secuencia del genoma del serogrupo A de N. meningitidis [80], aun cuando las regiones circundantes estén conservadas (> 90 %) entre los serogrupos A y B. Las referencias 10 y 11 desvelan formas polimórficas de 961. Se encontró que el gen estaba presente en el 91 % de las cepas del serogrupo B pertenecientes a los linajes hipervirulentos ET-5, ET-37 y el grupo A4, pero estaba ausente en todas las cepas ensayadas del linaje 3. La mayoría de las cepas del serogrupo C ensayadas fueron positivas aunque no perteneciesen a linajes hipervirulentos. Lo mismo ocurrió con las cepas del serogrupo B con serotipos 2a y 2b. Para el serogrupo A, una cepa perteneciente al subgrupo III fue positiva, mientras que las otras dos cepas pertenecientes al subgrupo IV-1 fueron negativas. 961 estaba ausente en N. gonorrhoeae y en las especies comensales N. lactamica y N. cinerea.
Las figuras 1 y 2 muestran dominios en la proteína 961.
Cuando la región anclada (dominio 9) de la proteína 961 se suprime ("961cL") y se expresa en E. coli, la proteína se exporta al periplasma y se segrega en el sobrenadante del cultivo.
Para investigar esto más, se construyeron mutantes de deleción en la región C-terminal de 961 (961cL-Δaro, 961cLΔcc, 961aL, 961aL-Δ1, 961aL-Δ2, 961aL-Δ3) sobre la base de aspectos estructurales (deleciones de residuos aromáticos en los casos del mutante 961cΔaro, y de las regiones de superenrollamiento para los otros). Se analizaron con respecto a expresión y secreción al periplasma y al sobrenadante del cultivo. En todos estos mutantes de deleción, la proteína se produce en gran cantidad, está presente en la fracción periplásmica y se libera al sobrenadante del cultivo.
1 -Solicitud de patente internacional WO01/64920.
2 -Solicitud de patente internacional WO01/64922.
3 -Solicitud de patente internacional WO99/24578.
4 -Solicitud de patente internacional WO99/36544.
5 -Solicitud de patente internacional WO99/57280.
6 -Solicitud de patente internacional WO00/22430.
7 -Solicitud de patente internacional WO00/66741.
8 -Solicitud de patente internacional WO00/71574.
9 -Solicitud de patente internacional WO01/04316.
10 -Solicitud de patente internacional PCT/IB02/03396.
11 -Comanducci y col. (2002) J Exp Med 195:1445-1454.
12 -Vaccine Design: subunit & adjuvant approach (1995) Powell y Newman (ISBN: 030644867X).
10
13 -Solicitud de patente internacional WO01/52885.
14 -Bjune y col. (1991) Lancet 338(8775):1093-1096.
15 -Fukasawa y col. (1999) Vaccine 17:295 -2958.
16 -Rosenqvist y col. (1998) Dev. Biol. Stand. 92:323-333.
5 17 -Costantino y col. (1992) Vaccine 10:691-698.
18 -Costantino y col. (1999) Vaccine 17:1251-1263.
19 -Solicitud de patente internacional PCT/IB02/03191.
20 -Watson (2000) Pediatr Infect Dis J 19:331-332.
21 -Rubin (2000) Pediatr Clin North Am 47:269-285, v.
22 -Jedrzejas (2001) Microbiol Mol Biol Rev 65:187-207
23 -Solicitud de patente internacional WO93/18150.
24 -Solicitud de patente internacional WO99/53310.
25 -Solicitud de patente internacional WO98/04702.
26 -Bell (2000) Pediatr Infect Dis J 19:1187-1188. 15 27 -Iwarson (1995) APMIS 103:321-326.
28 -Gerlich y col. (1990) Vaccine 8 Supl: S63-68 y 79-80.
29 -Hsu y col. (1999) Clin Liver Dis 3:901-915.
30 -Gustafsson y col. (1996) N. Engl. J. Med. 334:349-355.
31 -Rappuoli y col. (1991) TIBTECH 9:232-238.
32 -Vaccines (1988) eds. Plotkin y Mortimer. ISBN 0-7216-1946-0.
33 -Del Guidice y col. (1998) Molecular Aspects of Medicine 19:1-70.
34 -Solicitud de patente internacional WO00/02606.
35 -Kalman y col. (1999) Nature Genetics 21:385-389.
36 -Read y col. (2000) Nucleic Acids Res 28:1397-406. 25 37 -Shirai y col. (2000) J. Infect. Dis. 181(Suppl 3):S524-S527.
38 -Solicitud de patente internacional WO99/27105.
39 -Solicitud de patente internacional WO00/27994.
40 -Solicitud de patente internacional WO00/37494.
41 -Solicitud de patente internacional WO99/28475.
42 -Ross y col. (2001) Vaccine 19:4135-4142.
43 -Sutter y col. (2000) Pediatr Clin North Am 47:287-308.
44 -Zimmerman y Spann (1999) Am Fam Physician 59:113-118, 125-126.
45 -Dreesen (1997) Vaccine 15 Supl: S2-6.
46 -MMWR Morb Mortal Wkly Rep 1998 Jan 16; 47(1):12, 19. 35 47 -McMichael (2000) Vaccine 19 Supl 1:S101-107.
48 -Schuchat (1999) Lancet 353(9146):51-6.
49 -Documento WO02/34771.
50 -Dale (1999) Infect Dis Clin North Am 13:227-43, viii.
51 -Ferretti y col. (2001) PNAS USA 98: 4658-4663.
52 -Kuroda y col. (2001) Lancet 357(9264):1225-1240; véanse también las páginas 1218-1219.
53 -Ramsay y col. (2001) Lancet 357(9251):195-196.
54 -Lindberg (1999) Vaccine 17 Supl 2:S28-36.
55 -Buttery y Moxon (2000) J R Coll Physicians Lond 34:163-168.
56 -Ahmad y Chapnick (1999) Infect Dis Clin North Am 13:113-133, vii. 45 57 -Goldblatt (1998) J. Med. Microbiol 47:563-567.
58 -Patente europea 0 477 508.
59 -Patente de Estados Unidos 5.306.492.
60 -Solicitud de patente internacional WO98/42721.
61 -Conjugate Vaccines (eds. Cruse y col.) ISBN 3805549326, particularmente vol. 10:48-114.
62 -Hermanson (1996) Bioconjugate Techniques ISBN: 0123423368 o 012342335X.
63 -Solicitud de patente europea 0372501.
64 -Solicitud de patente europea 0378881.
65 -Solicitud de patente europea 0427347.
66 -Solicitud de patente internacional WO93/17712. 55 67 -Solicitud de patente internacional WO98/58668.
68 -Solicitud de patente europea 0471177.
69 -Solicitud de patente internacional WO00/56360.
70 -Solicitud de patente internacional WO00/61761.
71 -Robinson y Torres (1997) Seminars in Immunology 9:271-283.
72 -Donnelly y col. (1997) Annu Rev Immunol 15:617-648.
73 -Scott-Taylor y Dalgleish (2000) Expert Opin Investig Drugs 9:471-480.
74 -Apostolopoulos y Plebanski (2000) Curr Opin Mol Ther 2:441-447.
75 -Ilan (1999) Curr Opin Mol Ther 1:116-120.
76 -Dubensky y col. (2000) Mol Med 6:723-732. 65 77 -Robinson y Pertmer (2000) Adv Virus Res 55:1-74.
78 -Donnelly y col. (2000) Am JRespir Crit Care Med 162(4 Pt 2): S 190-193.
11
Claims (1)
-
imagen1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0121591 | 2001-09-06 | ||
GBGB0121591.2A GB0121591D0 (en) | 2001-09-06 | 2001-09-06 | Hybrid and tandem expression of neisserial proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2556770T3 true ES2556770T3 (es) | 2016-01-20 |
Family
ID=9921633
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES10179788.4T Expired - Lifetime ES2556770T3 (es) | 2001-09-06 | 2002-09-06 | Expresión híbrida y en tándem de proteínas procedentes de Neisseria |
ES10179755.3T Expired - Lifetime ES2523365T3 (es) | 2001-09-06 | 2002-09-06 | Expresión híbrida y en tandem de proteínas de Neisseria |
ES02777592T Expired - Lifetime ES2357503T3 (es) | 2001-09-06 | 2002-09-06 | Expresión híbrida y en tandem de proteínas de neisseria. |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES10179755.3T Expired - Lifetime ES2523365T3 (es) | 2001-09-06 | 2002-09-06 | Expresión híbrida y en tandem de proteínas de Neisseria |
ES02777592T Expired - Lifetime ES2357503T3 (es) | 2001-09-06 | 2002-09-06 | Expresión híbrida y en tandem de proteínas de neisseria. |
Country Status (18)
Country | Link |
---|---|
US (6) | US8980277B2 (es) |
EP (4) | EP2829549A3 (es) |
JP (4) | JP4511832B2 (es) |
CN (2) | CN100390196C (es) |
AT (1) | ATE496063T1 (es) |
AU (2) | AU2002339217B2 (es) |
BR (1) | BR0212363A (es) |
CA (1) | CA2459816C (es) |
CY (2) | CY1113218T1 (es) |
DE (1) | DE60238993D1 (es) |
DK (3) | DK2360176T3 (es) |
ES (3) | ES2556770T3 (es) |
GB (1) | GB0121591D0 (es) |
MX (2) | MXPA04002216A (es) |
NZ (3) | NZ537976A (es) |
PT (3) | PT2360176E (es) |
RU (2) | RU2339646C2 (es) |
WO (1) | WO2003020756A2 (es) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2278011A3 (en) * | 1998-01-14 | 2012-03-07 | Novartis Vaccines and Diagnostics S.r.l. | Neisseria meningitidis antigens |
AU761780B2 (en) | 1998-05-01 | 2003-06-12 | Glaxosmithkline Biologicals Sa | Neisseria meningitidis antigens and compositions |
US20070026021A1 (en) * | 1998-05-01 | 2007-02-01 | Chiron S.R.I. | Neisseria meningitidis antigens and compositions |
EP1228217B1 (en) | 1999-04-30 | 2012-11-21 | Novartis Vaccines and Diagnostics S.r.l. | Conserved neisserial antigens |
MXPA01011867A (es) * | 1999-05-19 | 2002-05-06 | Chiron Spa | Composiciones neisseriales de combinacion. |
GB9911683D0 (en) * | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
AU784203B2 (en) | 1999-10-29 | 2006-02-23 | Glaxosmithkline Biologicals S.A. | Neisserial antigenic peptides |
GB9928196D0 (en) | 1999-11-29 | 2000-01-26 | Chiron Spa | Combinations of B, C and other antigens |
EP2275129A3 (en) * | 2000-01-17 | 2013-11-06 | Novartis Vaccines and Diagnostics S.r.l. | Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins |
JP4763210B2 (ja) | 2000-02-28 | 2011-08-31 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | ナイセリアのタンパク質の異種発現 |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
GB0121591D0 (en) * | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
ATE469915T1 (de) | 2001-07-27 | 2010-06-15 | Novartis Vaccines & Diagnostic | Antikörper gegen das meningokokken adhäsin app |
AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
US7838015B2 (en) | 2001-10-03 | 2010-11-23 | Novartis Vaccines And Diagnostics, Inc. | Adjuvanted meningococcus compositions |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
EP2255826B1 (en) * | 2002-08-02 | 2016-04-13 | GlaxoSmithKline Biologicals S.A. | Neisserial vaccine compositions comprising a combination of antigens |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
US7785608B2 (en) | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
PT2353608T (pt) | 2002-10-11 | 2020-03-11 | Novartis Vaccines And Diagnostics S R L | Vacinas de polipéptidos para protecção alargada contra linhagens meningocócicas hipervirulentas |
AU2003288660A1 (en) | 2002-11-15 | 2004-06-15 | Chiron Srl | Unexpected surface proteins in neisseria meningitidis |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
DK1587537T3 (da) | 2003-01-30 | 2012-07-16 | Novartis Ag | Injicerbare vacciner mod multiple meningococ-serogrupper |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
SI1961426T1 (sl) * | 2003-10-02 | 2011-10-28 | Novartis Ag | Kombinirana cepiva proti meningitisu |
GB0408977D0 (en) * | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
GB0415160D0 (en) * | 2004-07-06 | 2004-08-11 | Chiron Srl | Inhibitors of bacterial infection |
GB0419408D0 (en) * | 2004-09-01 | 2004-10-06 | Chiron Srl | 741 chimeric polypeptides |
WO2006089264A2 (en) | 2005-02-18 | 2006-08-24 | Novartis Vaccines And Diagnostics Inc. | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli |
CN101180312A (zh) | 2005-02-18 | 2008-05-14 | 诺华疫苗和诊断公司 | 来自尿路病原性大肠杆菌的免疫原 |
AU2013201318B2 (en) * | 2005-11-25 | 2015-11-19 | Glaxosmithkline Biologicals Sa | Chimeric, hybrid and tandem polypeptides of meningococcal NMB 1870 |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
US20110008279A1 (en) * | 2005-12-06 | 2011-01-13 | Vega Masignani | Methods and Compositions Relating to Adhesins as Adjuvants |
US20100166788A1 (en) | 2006-08-16 | 2010-07-01 | Novartis Vaccines And Diagnostics | Immunogens from uropathogenic escherichia coli |
GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
CN101951949B (zh) | 2007-10-19 | 2013-10-02 | 诺华股份有限公司 | 脑膜炎球菌疫苗制剂 |
EP3263591B1 (en) | 2008-02-21 | 2019-03-27 | GlaxoSmithKline Biologicals S.A. | Meningococcal fhbp polypeptides |
NZ588191A (en) | 2008-03-03 | 2012-06-29 | Irm Llc | Compounds and compositions as tlr activity modulators |
ES2557282T3 (es) * | 2008-03-10 | 2016-01-25 | Children's Hospital & Research Center At Oakland | Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso |
CA2726512A1 (en) * | 2008-06-09 | 2009-12-17 | Novartis Ag | Antibodies against neisserial factor h binding protein |
WO2010070453A2 (en) * | 2008-12-17 | 2010-06-24 | Novartis Ag | Meningococcal vaccines including hemoglobin receptor |
PT2411048T (pt) | 2009-03-24 | 2020-07-14 | Glaxosmithkline Biologicals Sa | Proteína de ligação ao fator h meningocócica com adjuvante |
NZ595361A (en) * | 2009-04-30 | 2013-09-27 | Childrens Hosp & Res Ct Oak | Chimeric factor h binding proteins (fhbp) and methods of use |
WO2010144734A1 (en) | 2009-06-10 | 2010-12-16 | Novartis Ag | Benzonaphthyridine-containing vaccines |
ES2596653T3 (es) | 2009-06-16 | 2017-01-11 | Glaxosmithkline Biologicals Sa | Ensayos bactericidas de opsonización y dependientes de anticuerpo mediado por el complemento de alto rendimiento |
EP2470204B1 (en) | 2009-08-27 | 2015-12-16 | GlaxoSmithKline Biologicals SA | Hybrid polypeptides including meningococcal fhbp sequences |
TWI445708B (zh) | 2009-09-02 | 2014-07-21 | Irm Llc | 作為tlr活性調節劑之化合物及組合物 |
ES2443952T3 (es) | 2009-09-02 | 2014-02-21 | Novartis Ag | Composiciones inmunógenas que incluyen moduladores de la actividad de TLR |
AU2010302344A1 (en) | 2009-09-30 | 2012-04-26 | Novartis Ag | Expression of meningococcal fhbp polypeptides |
MX2012004850A (es) | 2009-10-27 | 2012-05-22 | Novartis Ag | Polipeptidos fhbp meningococicos modificados. |
WO2011057148A1 (en) | 2009-11-05 | 2011-05-12 | Irm Llc | Compounds and compositions as tlr-7 activity modulators |
CN102762206A (zh) | 2009-12-15 | 2012-10-31 | 诺华有限公司 | 免疫增强化合物的均匀悬液及其用途 |
JP5363381B2 (ja) * | 2010-03-09 | 2013-12-11 | パナソニック株式会社 | プラズマディスプレイパネル |
EA023725B1 (ru) | 2010-03-23 | 2016-07-29 | Новартис Аг | Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний |
CA2790167C (en) | 2010-03-30 | 2021-02-09 | Children's Hospital & Research Center Oakland | Factor h binding proteins (fhbp) with altered properties and methods of use thereof |
EP2585106A1 (en) | 2010-06-25 | 2013-05-01 | Novartis AG | Combinations of meningococcal factor h binding proteins |
MX350142B (es) | 2010-08-23 | 2017-08-28 | Wyeth Llc * | Formulaciones estables de antigenos rlp2086 de neisseria meningitidis. |
WO2012032498A2 (en) | 2010-09-10 | 2012-03-15 | Novartis Ag | Developments in meningococcal outer membrane vesicles |
EP3549601B1 (en) | 2010-09-10 | 2021-02-24 | Wyeth LLC | Non-lipidated variants of neisseria meningitidis orf2086 antigens |
CN102028941B (zh) * | 2011-02-11 | 2013-02-13 | 中国医学科学院医学生物学研究所 | 一种b群脑膜炎球菌重组蛋白嵌合疫苗及其制备方法 |
US20140186861A1 (en) * | 2011-07-11 | 2014-07-03 | Uvic Industry Partnerships Inc. | Soluble treponema pallidum protein tp0453, tp0453-tp0326 fusion protein, and use in syphilis diagnosis |
EP2797624A1 (en) | 2011-12-29 | 2014-11-05 | Novartis AG | Adjuvanted combinations of meningococcal factor h binding proteins |
MX359256B (es) | 2012-03-09 | 2018-09-19 | Pfizer | Composiciones de neisseria meningitidis y metodos de las mismas. |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
US10376573B2 (en) | 2012-06-14 | 2019-08-13 | Glaxosmithkline Biologicals Sa | Vaccines for serogroup X meningococcus |
JP2015524418A (ja) | 2012-07-27 | 2015-08-24 | アンスティテュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 血管内皮細胞への髄膜炎菌の線毛媒介接着の受容体としてのcd147 |
EP2964665B1 (en) | 2013-03-08 | 2018-08-01 | Pfizer Inc | Immunogenic fusion polypeptides |
SG11201600334SA (en) * | 2013-08-02 | 2016-02-26 | Children S Hospital & Res Ct Oakland | Non-naturally occurring factor h binding proteins (fhbp) and methods of use thereof |
RU2662968C2 (ru) | 2013-09-08 | 2018-07-31 | Пфайзер Инк. | Иммуногенная композиция против neisseria meningitidis (варианты) |
KR20160127104A (ko) | 2014-02-28 | 2016-11-02 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 변형된 수막구균 fhbp 폴리펩티드 |
EP4074726A3 (en) | 2014-07-23 | 2022-11-23 | Children's Hospital & Research Center at Oakland | Factor h binding protein variants and methods of use thereof |
CN107249626A (zh) | 2015-02-19 | 2017-10-13 | 辉瑞大药厂 | 脑膜炎奈瑟球菌组合物及其方法 |
US20180064801A1 (en) | 2016-09-02 | 2018-03-08 | Glaxosmithkline Biologicals Sa | Vaccines for neisseria gonorrhoeae |
SG11201906519RA (en) | 2017-01-31 | 2019-08-27 | Pfizer | Neisseria meningitidis compositions and methods thereof |
AU2022223712A1 (en) | 2021-02-19 | 2023-10-05 | Sanofi Pasteur Inc. | Meningococcal b recombinant vaccine |
GB202115151D0 (en) | 2021-10-21 | 2021-12-08 | Glaxosmithkline Biologicals Sa | Methods |
GB202208089D0 (en) | 2022-06-01 | 2022-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
GB202208093D0 (en) | 2022-06-01 | 2022-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
WO2024030931A1 (en) | 2022-08-03 | 2024-02-08 | Sanofi Pasteur Inc. | Adjuvanted immunogenic composition against neisseria meningitidis b |
Family Cites Families (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0196056B1 (en) * | 1985-03-28 | 1991-05-22 | Chiron Corporation | Improved expression using fused genes providing for protein product |
DE3622221A1 (de) | 1986-07-02 | 1988-01-14 | Max Planck Gesellschaft | Verfahren zur gentechnologischen gewinnung von proteinen unter verwendung gramnegativer wirtszellen |
EP0273116A3 (en) | 1986-10-09 | 1990-05-02 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Gonococcal and meningococcal polypeptides, vaccines and diagnostics |
GB8815795D0 (en) | 1988-07-02 | 1988-08-10 | Bkl Extrusions Ltd | Glazing bead |
DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
NL8803111A (nl) | 1988-12-19 | 1990-07-16 | Nederlanden Staat | Multivalent meningococcen klasse i buitenmembraaneiwit vaccin. |
ATE120093T1 (de) | 1988-12-19 | 1995-04-15 | Praxis Biolog Inc | Meningococcales klasse i-aussenmembranprotein- vakzin. |
ES2055785T3 (es) | 1989-01-17 | 1994-09-01 | Eniricerche Spa | Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas. |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
DK0504202T3 (da) * | 1989-12-14 | 1995-10-02 | Ca Nat Research Council | Forbedret meningokok-polysaccharid-konjugat vaccine |
CU22302A1 (es) | 1990-09-07 | 1995-01-31 | Cigb | Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales |
EP0467714A1 (en) | 1990-07-19 | 1992-01-22 | Merck & Co. Inc. | The class II protein of the outer membrane of neisseria meningitidis |
EP0471177B1 (en) | 1990-08-13 | 1995-10-04 | American Cyanamid Company | Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines |
US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
ATE174625T1 (de) | 1991-03-14 | 1999-01-15 | Imclone Systems Inc | Rekombinante hybride porinepitope |
JP3368902B2 (ja) | 1992-03-02 | 2003-01-20 | カイロン エセ.ピー.アー. | ワクチンおよび診断に有用なHelicobacterpyloriタンパク質 |
IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
FR2692592B1 (fr) | 1992-06-19 | 1995-03-31 | Pasteur Merieux Serums Vacc | Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant. |
ES2108278T3 (es) | 1992-06-25 | 1997-12-16 | Smithkline Beecham Biolog | Composicion de vacuna con coadyuvantes. |
WO1994021292A1 (en) | 1993-03-23 | 1994-09-29 | Smithkline Beecham Biologicals (S.A.) | Vaccine compositions containing 3-o deacylated monophosphoryl lipid a |
US5439808A (en) | 1993-07-23 | 1995-08-08 | North American Vaccine, Inc. | Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US6165747A (en) | 1993-12-30 | 2000-12-26 | President & Fellows Of Harvard College | Nucleic acids encoding hedgehog proteins |
FR2720408B1 (fr) | 1994-05-31 | 1996-08-14 | Pasteur Merieux Serums Vacc | Fragments Tbp2 de Neisseria meningitidis. |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
ATE328890T1 (de) | 1994-07-15 | 2006-06-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
IL117483A (en) | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
FR2739624B1 (fr) | 1995-10-10 | 1997-12-05 | Pasteur Merieux Serums Vacc | Nouvelle sous-unite tbp2 de neisseria meningitidis |
DE19630390A1 (de) | 1996-07-26 | 1998-01-29 | Chiron Behring Gmbh & Co | Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung |
EP1537877A3 (en) | 1996-10-11 | 2005-08-03 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
WO1998017805A2 (en) | 1996-10-24 | 1998-04-30 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, c/o Centers for Disease Control and Prevention, Technology Transfer Office | Invasion associated genes from neisseria meningitidis serogroup b |
EP1039935A4 (en) | 1997-02-28 | 2005-04-27 | Univ Iowa Res Found | USE OF NUCLEIC ACIDS CONTAINING NON-METHYLATED CpG DINUCLEOTIDES IN THE TREATMENT OF LIPOPOLYSACCHARIDE-ASSOCIATED ILLNESSES |
EP1005368B1 (en) | 1997-03-10 | 2009-09-02 | Ottawa Hospital Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants |
US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
US6339068B1 (en) | 1997-05-20 | 2002-01-15 | University Of Iowa Research Foundation | Vectors and methods for immunization or therapeutic protocols |
ATE252596T1 (de) | 1997-06-06 | 2003-11-15 | Dynavax Tech Corp | Immunstimulierende oligonucleotide, zusammensetzungen davon, und verfahren zur verwendung davon |
GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
EP1009382B1 (en) | 1997-09-05 | 2003-06-18 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
CA2308606A1 (en) | 1997-11-06 | 1999-05-20 | Chiron S.P.A. | Neisserial antigens |
US6914131B1 (en) | 1998-10-09 | 2005-07-05 | Chiron S.R.L. | Neisserial antigens |
DK1032674T3 (da) | 1997-11-21 | 2007-04-10 | Serono Genetics Inst Sa | Chlamydia pneumoniae genomisk sekvens og polypeptider, fragmenter deraf og anvendelser deraf, især til diagnosen, forebyggelsen og behandlingen af infektion |
WO1999028475A2 (en) | 1997-11-28 | 1999-06-10 | Genset | Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection |
GB9726398D0 (en) | 1997-12-12 | 1998-02-11 | Isis Innovation | Polypeptide and coding sequences |
EP2278011A3 (en) | 1998-01-14 | 2012-03-07 | Novartis Vaccines and Diagnostics S.r.l. | Neisseria meningitidis antigens |
CN1198937C (zh) | 1998-01-30 | 2005-04-27 | 第一三得利制药株式会社 | 利用辅助肽制造肽的方法 |
US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
GB9807721D0 (en) | 1998-04-08 | 1998-06-10 | Chiron Spa | Antigen |
BR9909915A (pt) | 1998-04-09 | 2000-12-26 | Smithkline Beecham Biolog | Composições adjuvantes |
US20070026021A1 (en) | 1998-05-01 | 2007-02-01 | Chiron S.R.I. | Neisseria meningitidis antigens and compositions |
AU761780B2 (en) | 1998-05-01 | 2003-06-12 | Glaxosmithkline Biologicals Sa | Neisseria meningitidis antigens and compositions |
US6248329B1 (en) * | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
MXPA01003557A (es) * | 1998-10-09 | 2004-04-05 | Chiron Corp | Secuencias genomicas de neisseria y metodos para su uso. |
EP2266604A3 (en) | 1998-10-16 | 2011-05-11 | GlaxoSmithKline Biologicals S.A. | Adjuvant systems and vaccines |
CA2347849C (en) * | 1998-10-22 | 2013-06-25 | The University Of Montana | Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof |
AU1722300A (en) | 1998-11-12 | 2000-05-29 | Regents Of The University Of California, The | Chlamydia pneumoniae genome sequence |
GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
DE60038166T2 (de) | 1999-03-19 | 2009-03-12 | Glaxosmithkline Biologicals S.A., Rixensart | Impfstoff gegen bakterielle antigene |
FR2791895B1 (fr) | 1999-03-23 | 2001-06-15 | Pasteur Merieux Serums Vacc | Utilisation de trehalose pour stabiliser un vaccin liquide |
EP1165796A2 (en) | 1999-04-09 | 2002-01-02 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
DK1187629T3 (da) | 1999-04-19 | 2005-01-17 | Glaxosmithkline Biolog Sa | Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid |
AU780308B2 (en) | 1999-04-30 | 2005-03-17 | J. Craig Venter Institute, Inc. | Neisseria genomic sequences and methods of their use |
EP1228217B1 (en) | 1999-04-30 | 2012-11-21 | Novartis Vaccines and Diagnostics S.r.l. | Conserved neisserial antigens |
MXPA01011867A (es) | 1999-05-19 | 2002-05-06 | Chiron Spa | Composiciones neisseriales de combinacion. |
GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
PL355232A1 (en) | 1999-09-24 | 2004-04-05 | Smithkline Beecham Biologicals S.A. | Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant |
CA2383413A1 (en) | 1999-09-24 | 2001-03-29 | Smithkline Beecham Biologicals S.A. | Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
AU784203B2 (en) | 1999-10-29 | 2006-02-23 | Glaxosmithkline Biologicals S.A. | Neisserial antigenic peptides |
EP2275129A3 (en) | 2000-01-17 | 2013-11-06 | Novartis Vaccines and Diagnostics S.r.l. | Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins |
HUP0300696A3 (en) | 2000-01-25 | 2004-10-28 | Univ Queensland Brisbane | Proteins comprising conserved regions of neisseria meningitidis surface antigen nhha |
JP4763210B2 (ja) * | 2000-02-28 | 2011-08-31 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | ナイセリアのタンパク質の異種発現 |
US20040167058A1 (en) * | 2000-06-29 | 2004-08-26 | Colgate-Palmolive Company | Multi-phase clear fabric softening composition |
US20040005667A1 (en) | 2000-07-03 | 2004-01-08 | Giuloi Ratti | Immunisation against chlamydia pneumoniae |
MX357775B (es) | 2000-10-27 | 2018-07-20 | J Craig Venter Inst Inc | Acidos nucleicos y proteinas de los grupos a y b de estreptococos. |
GB0108024D0 (en) * | 2001-03-30 | 2001-05-23 | Chiron Spa | Bacterial toxins |
RU2323002C2 (ru) | 2001-07-26 | 2008-04-27 | Чирон Срл. | Вакцины, содержащие алюминиевые адъюванты и гистидин |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
GB0121591D0 (en) * | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
ATE469915T1 (de) | 2001-07-27 | 2010-06-15 | Novartis Vaccines & Diagnostic | Antikörper gegen das meningokokken adhäsin app |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
EP2255826B1 (en) | 2002-08-02 | 2016-04-13 | GlaxoSmithKline Biologicals S.A. | Neisserial vaccine compositions comprising a combination of antigens |
US7785608B2 (en) | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
PT2353608T (pt) | 2002-10-11 | 2020-03-11 | Novartis Vaccines And Diagnostics S R L | Vacinas de polipéptidos para protecção alargada contra linhagens meningocócicas hipervirulentas |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
CA2512917A1 (en) | 2003-01-15 | 2004-08-05 | Wyeth Holdings Corporation | Methods for increasing neisseria protein expression |
DK1587537T3 (da) | 2003-01-30 | 2012-07-16 | Novartis Ag | Injicerbare vacciner mod multiple meningococ-serogrupper |
US20070253964A1 (en) | 2003-04-16 | 2007-11-01 | Zlotnick Gary W | Novel Immunogenic Compositions for the Prevention and Treatment of Meningococcal Disease |
SI1961426T1 (sl) | 2003-10-02 | 2011-10-28 | Novartis Ag | Kombinirana cepiva proti meningitisu |
GB0409748D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Lactoferrin cleavage |
GB0419408D0 (en) | 2004-09-01 | 2004-10-06 | Chiron Srl | 741 chimeric polypeptides |
TWI487535B (zh) | 2004-11-30 | 2015-06-11 | Centocor Inc | 類鐸受體3(toll like receptor3)拮抗劑,方法及用途 |
RU2432962C2 (ru) | 2005-01-27 | 2011-11-10 | Чилдрен'З Хоспитал Энд Рисерч Сентер Эт Окленд | Вакцины с использованием везикул на основе gna 1870 широкого спектра действия для профилактики заболеваний, вызываемых neisseria meningitidis |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
WO2008125985A2 (en) | 2007-04-11 | 2008-10-23 | Novartis Ag | Blocking interaction between pathogen factors and factor h to inhibit hemorrhagic syndromes |
JP5637848B2 (ja) | 2007-06-04 | 2014-12-10 | ノバルティス アーゲー | 髄膜炎ワクチンの製剤化 |
EP3263591B1 (en) | 2008-02-21 | 2019-03-27 | GlaxoSmithKline Biologicals S.A. | Meningococcal fhbp polypeptides |
ES2557282T3 (es) | 2008-03-10 | 2016-01-25 | Children's Hospital & Research Center At Oakland | Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso |
IT1394288B1 (it) | 2008-09-12 | 2012-06-06 | Novartis Vaccines & Diagnostic | Immunogeni di proteine che legano il fattore h. |
GB0819633D0 (en) | 2008-10-25 | 2008-12-03 | Isis Innovation | Composition |
PT2411048T (pt) | 2009-03-24 | 2020-07-14 | Glaxosmithkline Biologicals Sa | Proteína de ligação ao fator h meningocócica com adjuvante |
WO2012032498A2 (en) | 2010-09-10 | 2012-03-15 | Novartis Ag | Developments in meningococcal outer membrane vesicles |
-
2001
- 2001-09-06 GB GBGB0121591.2A patent/GB0121591D0/en not_active Ceased
-
2002
- 2002-09-06 EP EP14172613.3A patent/EP2829549A3/en not_active Withdrawn
- 2002-09-06 CN CNB028221877A patent/CN100390196C/zh not_active Expired - Fee Related
- 2002-09-06 DE DE60238993T patent/DE60238993D1/de not_active Expired - Lifetime
- 2002-09-06 BR BR0212363-0A patent/BR0212363A/pt not_active Application Discontinuation
- 2002-09-06 RU RU2004110230/13A patent/RU2339646C2/ru not_active IP Right Cessation
- 2002-09-06 RU RU2008122435/10A patent/RU2475495C2/ru not_active IP Right Cessation
- 2002-09-06 DK DK10179788.4T patent/DK2360176T3/en active
- 2002-09-06 US US10/488,786 patent/US8980277B2/en active Active
- 2002-09-06 AU AU2002339217A patent/AU2002339217B2/en active Active
- 2002-09-06 NZ NZ537976A patent/NZ537976A/en not_active IP Right Cessation
- 2002-09-06 WO PCT/IB2002/003904 patent/WO2003020756A2/en active IP Right Grant
- 2002-09-06 CN CN200810092103XA patent/CN101260148B/zh not_active Expired - Fee Related
- 2002-09-06 ES ES10179788.4T patent/ES2556770T3/es not_active Expired - Lifetime
- 2002-09-06 PT PT101797884T patent/PT2360176E/pt unknown
- 2002-09-06 JP JP2003525026A patent/JP4511832B2/ja not_active Expired - Fee Related
- 2002-09-06 AT AT02777592T patent/ATE496063T1/de active
- 2002-09-06 MX MXPA04002216A patent/MXPA04002216A/es active IP Right Grant
- 2002-09-06 EP EP02777592A patent/EP1423419B1/en not_active Expired - Lifetime
- 2002-09-06 PT PT02777592T patent/PT1423419E/pt unknown
- 2002-09-06 PT PT101797553T patent/PT2327719E/pt unknown
- 2002-09-06 CA CA2459816A patent/CA2459816C/en not_active Expired - Fee Related
- 2002-09-06 ES ES10179755.3T patent/ES2523365T3/es not_active Expired - Lifetime
- 2002-09-06 NZ NZ547145A patent/NZ547145A/en not_active IP Right Cessation
- 2002-09-06 NZ NZ532115A patent/NZ532115A/en not_active IP Right Cessation
- 2002-09-06 EP EP10179788.4A patent/EP2360176B1/en not_active Expired - Lifetime
- 2002-09-06 DK DK02777592.3T patent/DK1423419T3/da active
- 2002-09-06 ES ES02777592T patent/ES2357503T3/es not_active Expired - Lifetime
- 2002-09-06 DK DK10179755.3T patent/DK2327719T3/da active
- 2002-09-06 EP EP10179755.3A patent/EP2327719B1/en not_active Revoked
-
2004
- 2004-03-08 MX MX2012000967A patent/MX336118B/es unknown
-
2005
- 2005-09-05 JP JP2005256658A patent/JP2005350486A/ja not_active Withdrawn
-
2008
- 2008-10-24 AU AU2008234959A patent/AU2008234959B2/en not_active Ceased
-
2010
- 2010-07-23 JP JP2010166543A patent/JP5542276B2/ja not_active Expired - Fee Related
-
2011
- 2011-04-15 CY CY20111100383T patent/CY1113218T1/el unknown
- 2011-06-13 US US13/159,370 patent/US9011869B2/en not_active Expired - Fee Related
-
2012
- 2012-02-03 US US13/366,252 patent/US8840907B2/en not_active Expired - Fee Related
-
2013
- 2013-09-24 JP JP2013196675A patent/JP2014051497A/ja not_active Withdrawn
-
2014
- 2014-06-16 US US14/305,979 patent/US9056075B2/en not_active Expired - Fee Related
-
2015
- 2015-06-15 US US14/739,985 patent/US20150273044A1/en not_active Abandoned
- 2015-12-22 CY CY20151101166T patent/CY1117065T1/el unknown
-
2017
- 2017-11-02 US US15/802,347 patent/US20180169210A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2556770T3 (es) | Expresión híbrida y en tándem de proteínas procedentes de Neisseria | |
Lee et al. | EfrAB, an ABC multidrug efflux pump in Enterococcus faecalis | |
ES2436747T3 (es) | Variantes multiples de protenia NMB 1870 de meningococo | |
Chorev | The partial retro–inverso modification: a road traveled together | |
US20030044429A1 (en) | Toll-like receptor 5 ligands and methods of use | |
CN1404487A (zh) | 高纯度脂肽、脂肽胶束及其制备方法 | |
CN102552874A (zh) | 用于减少cd36表达的方法 | |
JP2009155344A (ja) | アジュバント化された抗原性髄膜炎菌性組成物 | |
CN1261896A (zh) | 诊断和预防莱姆病用的组合物的表面抗原和蛋白质 | |
US20170190755A1 (en) | Immunomodulatory compositions and methods for treating disease with modified host defense peptides | |
US20060134143A1 (en) | Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli | |
Miao et al. | Inhibition of bacterial RNA polymerases. Peptide metabolites from the cultures of Streptomyces sp. | |
US5000952A (en) | Polypeptide pertussis toxin vaccine | |
Oshima et al. | Immune recognition of botulinum neurotoxin type A: regions recognized by T cells and antibodies against the protective HC fragment (residues 855–1296) of the toxin | |
US20080131465A1 (en) | Group a Streptococcus Crge Protein | |
US5719064A (en) | Peptide diagnostics and therapeutics for spondyloarthropathies | |
AU769157B2 (en) | Novel pyrrhocoricin-derived peptides, and methods of use thereof | |
EP1485466A2 (en) | Methods for treating diseases or conditions with peptide constructs | |
EP0785947B1 (en) | Peptides endowed with antiinflammatory activity | |
WO2011103458A2 (en) | Compositions and methods for using and identifying antimicrobial agents | |
Scioli et al. | New Teixobactin Analogues with a Total Lactam Ring | |
JP4166408B2 (ja) | 新規タキキニンペプチドおよびその前駆体ポリペプチドならびにこれらをコードする遺伝子 | |
US7015309B1 (en) | Pyrrhocoricin-derived peptides, and methods of use thereof | |
JP5795079B2 (ja) | 細胞表面で発現される抗菌ペプチド多重合複合体 | |
US20060134126A1 (en) | Peptide constructs for treating disease |